FAPI Radionuclide Theranostics Show Promise in Sarcoma Diagnosis and Treatment
FAPI PET and radionuclide therapy have been shown to improve detection and disease control in sarcoma patients, with higher detection rates than standard FDG PET and a 64.7% disease control rate with minimal severe adverse events.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E‑Mutated Colorectal Cancer
- Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
- Three Versus 6 Months of Adjuvant Oxaliplatin‑Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics